Treating bone marrow cancers linked to PARP inhibitor use in ovarian cancer survivors
Official title: Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients
Funded at Mayo Clinic Rochester · NIH-11308742 · Data updated 2026-11-12
Researchers are developing new drug strategies to treat aggressive bone marrow cancers that can occur after PARP inhibitor therapy in ovarian cancer survivors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $462,795 |
| NIH project number | 5R01CA289285-03 |
| Project ID | NIH-11308742 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are ovarian cancer survivors who develop therapy-related myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor treatment, especially those whose leukemia shows TP53 inactivation.
✕Less likely to help
Patients without therapy-related myeloid neoplasms or whose leukemia is unrelated to prior PARP inhibitor exposure or driven by different genetic changes may not benefit from this work.
What this research studies
This project focuses on bone marrow disorders (myelodysplastic syndrome and acute myeloid leukemia) that can arise after ovarian cancer patients receive PARP inhibitor drugs. The team is studying why these cancers often have TP53 gene defects and is testing drugs that block DNA‑damage checkpoints (CHK1, WEE1, and ATR inhibitors) in lab-grown cells, mouse tumor models, and patient leukemia samples. The goal is to find treatments that work against these hard-to-treat, TP53‑mutant cases and to identify which patients might benefit. Promising results would support moving these approaches toward clinical testing.
Why it matters
Potential benefit: Could lead to new therapies that improve survival and reduce relapse for ovarian cancer survivors who develop PARP inhibitor–associated myeloid neoplasms.
How similar studies have gone: Preclinical studies of replication checkpoint inhibitors have shown antileukemic effects in cell lines, animal models, and patient samples, but their clinical benefit in humans remains unproven.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Kaufmann, Scott H — Mayo Clinic Rochester
- Study coordinator: Kaufmann, Scott H
Related research
Other NIH-funded projects on the same topics.
-
Early blood changes and treatment-related leukemia risk after ovarian cancer
This project follows ovarian cancer survivors to look for early blood cell changes that can lead to treatment-related leukemia.
-
Improving treatment for blood cancers in ovarian cancer survivors
This study is looking for better treatment options for ovarian cancer patients who develop serious blood disorders after using certain medications, especially those with a specific gene mutation that makes standard treatments less effective, so they can live longer and feel better.
-
Investigating blood disorders in ovarian cancer survivors
This study is looking at how treatments for ovarian cancer might cause blood disorders later on, and it's for ovarian cancer survivors who want to help researchers find ways to prevent these issues and improve future treatments.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.